- ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results
- ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand
- ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)
- ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
- ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day
- ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024
- ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study
- ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024
- ARS Pharma Announces Favorable Topline Results from Repeat Dosing Study of neffy® (Epinephrine Nasal Spray) Under Nasal Allergen Challenge Conditions, Readies Data for Response to FDA’s Complete Response Letter
- ARS Pharmaceuticals to Present Positive Clinical Efficacy Data for neffy® (epinephrine nasal spray) at 2024 AAAAI Annual Meeting
More ▼
Key statistics
On Tuesday, ARS Pharmaceuticals Inc (SPRY:NMQ) closed at 8.83, -21.65% below its 52-week high of 11.27, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.13 |
---|---|
High | 9.15 |
Low | 8.81 |
Bid | 8.59 |
Offer | 9.50 |
Previous close | 8.83 |
Average volume | 324.88k |
---|---|
Shares outstanding | 96.90m |
Free float | 68.82m |
P/E (TTM) | -- |
Market cap | 855.59m USD |
EPS (TTM) | -0.5198 USD |
Data delayed at least 15 minutes, as of May 21 2024 21:00 BST.
More ▼